uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Developments in the synthesis of the antiplatelet and antithrombotic drug (S)-clopidogrel
Quaid I Azam Univ, Dept Chem, Islamabad 45320, Pakistan..ORCID iD: 0000-0002-7112-9296
Quaid I Azam Univ, Dept Chem, Islamabad 45320, Pakistan..ORCID iD: 0000-0002-3738-9692
Quaid I Azam Univ, Dept Chem, Islamabad 45320, Pakistan..
Quaid I Azam Univ, Dept Chem, Islamabad 45320, Pakistan..
Show others and affiliations
2017 (English)In: Chirality, ISSN 0899-0042, E-ISSN 1520-636X, Vol. 29, no 11, p. 684-707Article, review/survey (Refereed) Published
Abstract [en]

S-(+)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate, also known as (S)-clopidogrel, is marketed under the trade names Plavix and Iscover. It is a potent thienopyridine-class of antithrombotic and antiplatelet drug (antiaggregant). Among the two available stereoisomers of clopidogrel, for pharmaceutical activities only the S-enantiomer is applicable, as no antithrombotic activity is observed in the R-enantiomer and causes political upheavals and social turmoil in animal experiments. Worldwide sales of Plavix amounted to $6.4 billion yearly, which ranks second. Attributed to the increased demand of (S)-clopidogrel drug, it provoked the synthetic community to devise facile synthetic approaches. This review aims to summarize the synthetic methods of (S)-clopidogrel drug reported in the literature. The present review discusses the pros and cons of each synthetic methodology, which would be beneficial to the scientific community for further developments in the synthetic methodologies for (S)-clopidogrel. In addition, the compilation approach of literature-reported synthetic strategies of (S)-clopidogrel in one platform is advantageous, supportive, and crucial for the synthetic community to elect the best synthetic methodology of (S)-clopidogrel and to create new synthesis ideas.

Place, publisher, year, edition, pages
2017. Vol. 29, no 11, p. 684-707
Keywords [en]
antiaggregant, antiplatelet, antithrombotic, clopidogrel, iscover, Plavix
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-346833DOI: 10.1002/chir.22742ISI: 000412662100005PubMedID: 28875522OAI: oai:DiVA.org:uu-346833DiVA, id: diva2:1194717
Available from: 2018-04-03 Created: 2018-04-03 Last updated: 2018-04-03Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Saeed, AamerShahzad, Danish
By organisation
Farmakognosi
In the same journal
Chirality
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 15 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf